Comparing the current results to its competitors, Foghorn Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by -45.11 %, despite the revenue increase by the most of its competitors of 9.96 %, recorded in the same quarter.
Foghorn Therapeutics Inc , slower than the average decrease reported by the company's competitors of -30.93 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -30.93 %
Foghorn Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes major pharmaceutical firms, specialty pharmaceutical companies, biotechnology enterprises, academic research institutions, governmental agencies, and both public and private research organizations worldwide. Competitors often possess greater financial resources and expertise in areas such as research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals, and marketing. Smaller or early-stage companies may also present competition, particularly through partnerships with larger firms. Competitors may develop products targeting the chromatin regulatory system or other genetic expression mechanisms, potentially with more favorable profiles or at a faster pace. Competition extends to recruiting qualified personnel, establishing clinical trial sites, patient enrollment, and acquiring complementary technologies. Competitors may discover, develop, license, or commercialize products before or more successfully than the company.
April 28, 2025
In a recent press release, Foghorn Therapeutics shared compelling preclinical data about their innovative endeavors in cancer therapy development. The company has made significant expansions in its pipeline, focusing on the promising capabilities of FHD-909, a selective SMARCA2 inhibitor, which is strategically moving forward in a Phase 1 clinical trial. This trial specifically targets cancers with SMARCA4 (BRG1) mutations, placing a significant emphasis on non-small cell lung cancer (NSCLC) as the primary target population. Innovation in Cancer Therapy: A Closer Look Foghorn Therapeutics pipeline includes three major components of interest: SMARCA2 inhibitor FHD-909, selective CBP (CREB binding protein), a...
April 9, 2024
Foghorn Therapeutics Unveils Promising Preclinical Data for FHD-909, a Potential Breakthrough in Cancer TreatmentCombining the power of targeted therapies with the potential of groundbreaking research, Foghorn Therapeutics has presented compelling preclinical data on their avant-garde oncology programs. With a focus on the first-in-class BRM selective inhibitor FHD-909, the company showcased its remarkable tolerability and dose-dependent single agent activity, offering hope for patients with BRG1 mutated cancers. These findings bring us closer to the realization of a novel treatment option that holds immense promise in combating a wide range of challenging malignancies.The study, which was conducted by Fogho...
February 8, 2024
In an exciting development for the field of precision medicine, Foghorn Therapeutics Inc. has recently announced that its novel oral BRM selective inhibitor, FHD-909, has been selected by pharmaceutical giant Lilly for clinical development. This cutting-edge therapy holds immense potential in treating a specific subset of non-small cell lung cancer (NSCLC) patients with BRG1 mutations, revolutionizing the landscape of targeted lung cancer therapy. This article aims to present the facts surrounding this important milestone and assess its impact on Foghorn Therapeutics.FHD-909: A Breakthrough in Targeted Therapy:FHD-909 is a first-in-class oral BRM selective inhibitor developed by Foghorn Therapeutics, intende...
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Sources:
Foghorn Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Foghorn Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
